Understanding the concept of Nattokinase use: a few years after beginning

References

• Maslarov D. Cerebrovascular diseases: recent evaluations and ideas for improving the public health [dissertation]. Sofia: Medical University of Sofia; 2017.
   Google Scholar
• Milanov I, Stamenova P. National consensus statement for prophylaxis, making the diagnosis and treatment of cerebrovascular diseases. Bulg Neurol. 2020;21(S4):1–10.
   Google Scholar
• Kolmos M, Christoffersen L, Kruuse C. Recurrent ischemic stroke: a systematic review and meta-analysis. J Stroke Cerebrovasc Dis. 2021;30(8):105935. doi: 10.1016/j.jstrokecerebrovasdis.2021.105935.
   PubMed Web of Science ®Google Scholar
• Folsom AR, Yatsuya H, Nettleton JA, et al. Community prevalence of ideal cardiovascular health, by the American Heart Association definition, and relationship with cardiovascular disease incidence. J Am Coll Cardiol. 2011;57(16):1690–1696. doi: 10.1016/j.jacc.2010.11.041.
   PubMed Web of Science ®Google Scholar
• Rutten-Jacobs LC, Maaijwee NA, Arntz RM, et al. Risk factors and prognosis of young stroke. The FUTURE study: a prospective cohort study. Study rationale and protocol. BMC Neurol. 2011;11:109. doi: 10.1186/1471-2377-11-109.
   PubMed Web of Science ®Google Scholar
• Rutten-Jacobs LC, Arntz RM, Maaijwee NA, et al. Long-term mortality after stroke among adults aged 18 to 50 years. JAMA. 2013;309(11):1136–1144. doi: 10.1001/jama.2013.842.
   PubMed Web of Science ®Google Scholar
• Sumi H, Hamada H, Tsushima H, et al. A novel fibrinolytic enzyme (nattokinase) in the vegetable cheese Natto; a typical and popular soybean food in the Japanese diet. Experientia. 1987;43(10):1110–1111. doi: 10.1007/BF01956052.
   PubMedGoogle Scholar
• Chen H, McGowan EM, Ren N, et al. Nattokinase: a promising alternative in prevention and treatment of cardiovascular diseases. Biomark Insights. 2018;13:1177271918785130. doi: 10.1177/1177271918785130.
   Web of Science ®Google Scholar
• Ahmed HH, Nevein NF, Karima A, et al. Miracle enzymes serrapeptase and nattokinase mitigate neuroinflammation and apoptosis associated with Alzheimer’s disease in experimental model. WJPPS. 2013;3:876–891.
   Google Scholar
• Urano T, Ihara H, Umemura K, et al. The profibrinolytic enzyme subtilisin NAT purified from Bacillus subtilis cleaves and inactivates plasminogen activator inhibitor type 1. J Biol Chem. 2001;276(27):24690–24696. doi: 10.1074/jbc.M101751200.
   PubMed Web of Science ®Google Scholar
• Maslarov D, Drenska D. Nattokinase in patients with acute ischemic stroke and TIA—preliminary data. XVII National Congress of Neurology with international participation. Bulg Neurol. 2018;19(2):44A–121.
   Google Scholar
• Maslarov D, Drenska D. Use of nattokinase in patients with ischemic stroke and transient ischemic attacks. Neurol Neurosci. 2020;1(2):1–5.
   Google Scholar
• Folstein MF, Folstein SE, McHugh PR. Mini-mental state: a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res. 1975;12(3):189–198. doi: 10.1016/0022-3956(75)90026-6.
   PubMed Web of Science ®Google Scholar
• Nasreddine ZS, Phillips NA, Bédirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool for mild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695–699. doi: 10.1111/j.1532-5415.2005.53221.x.
   PubMed Web of Science ®Google Scholar
• Krousel-Wood MA, Chambers RB, Muntner P. Clinicians’ guide to statistics for medical practice and research: part I. Ochsner J. 2006;6:68–83.
   PubMedGoogle Scholar
• Krousel-Wood MA, Chambers RB, Muntner P. Clinicians’ guide to statistics for medical practice and research: part II. Ochsner J. 2007;7(1):3–7.
   PubMedGoogle Scholar
• Kim JY, Gum SN, Paik JK, et al. Effects of nattokinase on blood pressure: a randomized, controlled trial. Hypertens Res. 2008;31(8):1583–1588. doi: 10.1291/hypres.31.1583.
   PubMed Web of Science ®Google Scholar
• Jensen GS, Lenninger M, Ero MP, et al. Consumption of nattokinase is associated with reduced blood pressure and von Willebrand factor, a cardiovascular risk marker: results from a randomized, double-blind, placebo-controlled, multicenter North American clinical trial. Integr Blood Press Control. 2016;9:95–104. doi: 10.2147/IBPC.S99553.
   PubMedGoogle Scholar
• Ren NN, Chen HJ, Li Y, et al. A clinical study on the effect of nattokinase on carotid artery atherosclerosis and hyperlipidaemia. Zhonghua yi xue za zhi. 2017;97(26):2038–2042 (in Chinese).
   PubMedGoogle Scholar
• Xie S, Yu Z, Liu X. Preparation of nattokinase and study on its hypolipidemic effect. Chin J Biochem Pharm. 2015;35:17–20.
   Google Scholar
• Li D, Hou L, Hu M, et al. Recent advances in nattokinase-enriched fermented soybean foods: a review. Foods. 2022;11(13):1867. doi: 10.3390/foods11131867.
   PubMed Web of Science ®Google Scholar
• Wu D, Lin C, Lee M. Lipid-Lowering effect of nattokinase in patients with primary hypercholesterolemia. Acta Cardiol Sin. 2009;25:26–30.
   Web of Science ®Google Scholar
• Suzuki Y, Kondo K, Ichise H, et al. Dietary supplementation with fermented soybeans suppresses intimal thickening. Nutrition. 2003;19(3):261–264. doi: 10.1016/s0899-9007(02)00853-5.
   PubMed Web of Science ®Google Scholar
• Simova I, Simov D, Klisurski M, et al. Nattokinase-fibrinolytic, antihypertensive and lipid-lowering potential: an application in clinical practice. MD XV. 2018;1:87–89 (in Bulgarian).
   Google Scholar
• Chen H, Chen J, Zhang F, et al. Effective management of atherosclerosis progress and hyperlipidemia with nattokinase: a clinical study with 1,062 participants. Front Cardiovasc Med. 2022;9:964977. doi: 10.3389/fcvm.2022.964977.
   PubMed Web of Science ®Google Scholar
• Ji H, Yu L, Liu K, et al. Mechanisms of nattokinase in protection of cerebral ischemia. Eur J Pharmacol. 2014;745:144–151. doi: 10.1016/j.ejphar.2014.10.024.
   PubMed Web of Science ®Google Scholar
• Wang JM, Chen HY, Cheng SM, et al. Nattokinase reduces brain infarction, fibrinogen and activated partial thromboplastin time against cerebral ischemia-reperfusion injury. J Food Drug Anal. 2012;3:686–691.
   Google Scholar
• Hsu R-L, Lee K-T, Wang J-H, et al. Amyloid-degrading ability of nattokinase from Bacillus subtilis natto. J Agric Food Chem. 2009;57(2):503–508. doi: 10.1021/jf803072r.
   PubMed Web of Science ®Google Scholar
• Ahn YJ, Kim MH, Kim J, et al. Neuroprotective effect of nattokinase mediated by inhibition of platelet aggregation and thrombosis in photo thrombotic stroke. Stroke. 2015;46(suppl_1):A-PW262. doi: 10.1161/str.46.suppl_1.wp262.
   Google Scholar
• Lo JW, Crawford JD, Desmond DW, et al. Long-term cognitive decline after stroke: an individual participant data meta-analysis. Stroke. 2022;53(4):1318–1327. doi: 10.1161/STROKEAHA.121.035796.
   PubMed Web of Science ®Google Scholar
• Zhu Y, Zhao S, Fan Z, et al. Evaluation of the mini-mental state examination and the Montreal cognitive assessment for predicting post-stroke cognitive impairment during the acute phase in Chinese minor stroke patients. Front Aging Neurosci. 2020;12:236. doi: 10.3389/fnagi.2020.00236.
   PubMed Web of Science ®Google Scholar
• Wu H, Wang Y, Zhang Y, et al. Breaking the vicious loop between inflammation, oxidative stress and coagulation, a novel anti-thrombus insight of nattokinase by inhibiting LPS-induced inflammation and oxidative stress. Redox Biol. 2020;32:101500. doi: 10.1016/j.redox.2020.101500.
   PubMed Web of Science ®Google Scholar
• Pais E, Alexy T, Holsworth REJr, et al. Effects of nattokinase, a pro-fibrinolytic enzyme, on red blood cell aggregation and whole blood viscosity. Clin Hemorheol Microcirc. 2006;35(1–2):139–142.
   PubMed Web of Science ®Google Scholar
• Hsia CH, Shen MC, Lin JS, et al. Nattokinase decreases plasma levels of fibrinogen, factor VII, and factor VIII in human subjects. Nutr Res. 2009;29(3):190–196. doi: 10.1016/j.nutres.2009.01.009.
   PubMed Web of Science ®Google Scholar
• Kurosawa Y, Nirengi S, Homma T, et al. A single-dose of oral nattokinase potentiates thrombolysis and anti-coagulation profiles. Sci Rep. 2015;5(1):11601. doi: 10.1038/srep11601.
   PubMedGoogle Scholar
• Weng Y, Yao J, Sparks S, et al. Nattokinase: an oral antithrombotic agent for the prevention of cardiovascular disease. Int J Mol Sci. 2017;18:e523. doi: 10.3390/ijms18030523.
   PubMed Web of Science ®Google Scholar
• Petrovsky P. Stroke prevention in patients with atrial fibrillation using the natural product nattokinase as an alternative of conventional anticoagulation. Bulgarian Cardiology XXIII. 2017;4:51–55 (in Bulgarian).
   Google Scholar
• Maslarov D, Gabrovski N. [Farmakologichno I nefarmacologichno lechenie na ishemichen mozachen insult.] Pharmacological and non-pharmacological treatment of ischemic stroke. [Nauka Farmakologia] Sci Pharmacol. 2013;2(7):43–49 (in Bulgarian).
   Google Scholar
• Gallelli G, Di Mizio G, Palleria C, et al. Data recorded in real life support the safety of nattokinase in patients with vascular diseases. Nutrients. 2021;13:2031. doi: 10.3390/nu13062031.
   PubMed Web of Science ®Google Scholar
• Liu Y, Han Y, Cao L, et al. Analysis of main components and prospects of natto. AER. 2021;9(1):1–9. doi: 10.4236/aer.2021.91001.
   Google Scholar
• Muresanu DF. Neuroprotection and neuroplasticity: a holistic approach and future perspectives. J Neurol Sci. 2007;257(1-2):38–43. doi: 10.1016/j.jns.2007.01.041.
   PubMed Web of Science ®Google Scholar
• Muresanu DF, Buzoianu A, Florian SI, et al. Towards a roadmap in brain protection and recovery. J Cell Mol Med. 2012;16(12):2861–2871. doi: 10.1111/j.1582-4934.2012.01605.x.
   PubMed Web of Science ®Google Scholar